Analysis of immunological status using CFSE-MLR for de-novo kidney transplant recipients who are treated with Everolimus commencing 3 months after surgery.
Not Applicable
- Conditions
- After kidney transplantation
- Registration Number
- JPRN-UMIN000010743
- Lead Sponsor
- Trasnplantation surgery, Hiroshima University Hospital
- Brief Summary
o significant difference was found between reduced Cyclosporine plus Everolimus group and normal dose Cyclosporine group in CFSE-MLR categorization.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
rejection severe proteinuria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of CFSE-MLR categorization between reduced Cyclosporine plus Everolimus group and normal dose Cyclosporine group.
- Secondary Outcome Measures
Name Time Method